EDGE Unveils First UAE-made Family of Smart Loitering Munitions at IDEX 2021
EDGE, an advanced technology group for defence and beyond, today launches its first family of multirotor loitering munitions, the QX range. In addition, Shadow 50 and Shadow 25, Rash 2 gliding munition kit, as well as new variants of the RW24 range – all designed and manufactured in the company’s first year of operations – were unveiled on the first day of the International Defence Exhibition and Conference (IDEX 2021), that is underway at the Abu Dhabi National Exhibition Centre until 25 February.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210221005030/en/
EDGE launches QX range- its first family of multirotor loitering munitions (Photo: AETOSWire)
The unveiling of the Class-1 electric unmanned aerial vehicles (UAVs) took place at the EDGE pavilion in the presence of His Excellency Faisal Al Bannai, CEO and Managing Director of EDGE and Ali Al Yafei, CEO of ADASI.
His Excellency Faisal Al Bannai, CEO & Managing Director, EDGE, said: “Right now, drone technology is revolutionising our world with the full potential of unmanned and autonomous capabilities still to be further explored – not just in the military sector, but the commercial sector too.”
He added: “Through launching the first UAE-made family of smart loitering drones, EDGE marks a significant milestone as a key technology enabler and in boosting the country’s autonomous capabilities and AI integration. With the future increasingly relying on unmanned systems that provide a higher degree of tactical flexibility, we have invested extensively to fast-track R&D investments in these domains, bringing related products to market with speed.”
The QX family of loitering munitions comprises four products: QX-1, a micro-UAV, QX-2, a mini-UAV, QX-3, a small UAV, and QX-4, which features an impressive vertical take-off and landing (VTOL) fixed wing. The precision-guided systems use sophisticated AI algorithms to target and strike, boasting an accuracy of 1 m CEP (circular error probable) – with an aim similar to laser guided munitions. Built to launch in any environment or terrain, the entire QX family of UAVs are lightweight, man portable, and comprise VTOL capabilities.
The second range of loitering munitions consists of Shadow 50 and Shadow 25. As the name implies, Shadow 50 can carry a payload of 50kg – exactly double its counterpart. Shadow 25 is a high-speed system equipped with a jet engine and boasts a short reaction time. Delivering high precision strike against fixed targets and advanced guidance capabilities, these UAVs leverage Global Navigation Satellite Systems (GNSS) and can fly using video navigation systems in GPS denied Environment.
Also launched on Day 1 of IDEX, the Rash 2 is a fixed-wing guidance kit for mortars and other in-house designed payloads, capable of gliding in flight and directing munitions to ground targets, available in different sizes to accommodate varying payload capacity, range, and endurance. ADASI has secured AED 55 million contract to supply Rash 2 to the UAE Armed Forces, marking the first order of the newly launched product.
Three new additions to the RW-24 range were also launched in time for IDEX 2021. The newly unveiled RW-24 Seeker is equipped with a thermal automatic seeker that enable greater accuracy of engagement of moving targets and increased functionality within GPS-denied environments.
The RW-24 Extended Warhead and RW-24 Extended Range variants increase the payload capacity from 8 kg to 13 kg, enabling the drone to carry additional fuel or to increase the size of the warhead.
EDGE is an advanced technology group that ranks among the top 25 military suppliers in the world.
About EDGE
EDGE is an advanced technology group established to develop agile, bold and disruptive solutions for defence and beyond. Enabling a secure future, it is dedicated to bringing innovative technologies and services to market with greater speed and efficiency. Consolidating over 25 entities and employing more than 13,000 brilliant minds, it offers expertise across five core clusters: Platforms & Systems, Missiles & Weapons, Cyber Defence, Electronic Warfare & Intelligence and Mission Support. Headquartered in Abu Dhabi, United Arab Emirates, EDGE is a catalyst for change – set to revolutionise the industry and change its fundamentals.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210221005030/en/
Contact information
Thushara Mohanan
media@edgegroup.ae
+971-555080413/ +971-55-3584520
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom